key: cord-0430849-ngxx1zvm
authors: Bizzarri, D.; Reinders, M. J. T.; Beekman, M.; Slagboom, P. E.; BBMRI-nl,; van den Akker, E. B.
title: 1H-NMR metabolomics-based surrogates to impute common clinical risk factors and endpoints
date: 2021-07-22
journal: nan
DOI: 10.1101/2021.07.19.21258470
sha: 06e38209c2c71c6e5d171e53068dff656520b49c
doc_id: 430849
cord_uid: ngxx1zvm

Missing or incomplete phenotypic information can severely deteriorate the statistical power in epidemiological studies. High-throughput quantification of small-molecules in bio-samples, i.e. metabolomics, is steadily gaining popularity, as it is highly informative for various phenotypical characteristics. Here we aim to leverage metabolomics to impute missing data in clinical variables routinely assessed in large epidemiological and clinical studies. To this end, we have employed ~25,000 1H-NMR metabolomics samples from 28 Dutch cohorts collected within the BBMRI-NL consortium, to create 19 metabolomics-based predictors for clinical variables, including diabetes status (AUC5-Fold CV = 0.94) and lipid medication usage (AUC5-Fold CV = 0.90). Subsequent application in independent cohorts confirmed that our metabolomics-based predictors can indeed be used to impute a wide array of missing clinical variables from a single metabolomics data resource. In addition, application highlighted the potential use of our predictors to explore the effects of totally unobserved confounders in omics association studies. Finally, we show that our predictors can be used to explore risk factor profiles contributing to mortality in older participants. To conclude, we provide 1H-NMR metabolomics-based models to impute clinical variables routinely assessed in epidemiological studies and illustrate their merit in scenarios when phenotypic variables are partially incomplete or totally unobserved.

A major goal in biomedical research is to find faithful biomarkers of health, defined as 38 accurate and reproducible assays that provide objective indications on the health of an 39 individual and his/her risk of developing a disease over predefined time trajectory [1] . Over 40 the years, many types of putative biomarkers have been proposed, ranging from environmental 41 factors to biochemical assays, that may aid the diagnosis and prognostication of disease, 42 including cardiovascular disease, cancer and immunological disorders. Many of these clinical 43 variables, however, are costly or cumbersome to obtain, especially for more critical and frail 44 participants, such as older individuals [2], [3] . Consequently, missing data frequently occurs in 45 large epidemiological or clinical studies, potentially leading to a significant loss of statistical 46 power, thus impeding biomarker research in studies of older individuals [4] . 47

Missing phenotypic data can be handled in various ways. Often, analyses are either 48 restricted to individuals or variables with complete data, which both may introduce potential 49 biases [5] . Alternatively, missing data can be imputed using complete phenotypic variables [4] , 50

[6]-[8], yet these approaches work only satisfactory if the complete phenotypic variables are 51 informative for the ones with missing observations. A third solution basically extents the 52 second approach by leveraging informative omics data to impute missing phenotypic data. 53

Particularly useful in this context are metabolite quantifications in minimally invasive 54 biomaterials, such as urine, saliva or blood plasma, obtained with proton Nuclear Magnetic 55

Resonance ( 1 H-NMR) assays [9] . Although this technique only captures a modest number of 56 analytes, 1 H-NMR metabolomics data is frequently acquired in large-scale epidemiological 57 studies, as it is a cost-efficient and reproducible data resource. The underlying motivation is 58 that metabolite concentrations in blood seem to be direct readouts of various biological 59 processes, incorporating cues of the environment as well as the host's genetic background, and 60 hence may be regarded as intermediate phenotypes. Indeed, metabolomics has been shown to 61 capture information on the effect of drug treatments [10] cardiometabolic clinical endpoints (diabetes and metabolic syndrome). Acquiring data for all 76 these variables is costly and requires sufficient biomaterial, meaning that not every study has 77 collected the same set of data. We further explored these methods to establish metabolic 78 surrogate values in the Leiden Longevity Study, which we used to showcase possible 79 applications in epidemiological research. We showed the validity of the surrogates in an 80 external cohort comparing them to the original values, we examined their association to further 81 clinically valuable cardiometabolic health markers, and explored whether the metabolic 82 surrogates associate, separately or combined, to all-cause mortality. 83 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Figure 1A ) 113 for 20 conventional clinical variables ( Figure 1B) whereas chronological age was split into three categories ( Figure 1B ). Overall, we were able 125 to construct and evaluate 20 variables mainly representing risk factors of cardio-metabolic 126 health that are routinely assessed in epidemiological and clinical studies. 127

Logistic Elastic-NET regression models were trained for each of the 20 dichotomous 128 variables, measured in at least 6 of the BBMRI studies, in both healthy and diseased 129 individuals. Model development was performed in two loops to prevent overtraining. An inner 130 loop of 5-Fold Cross Validation with 5 repetitions was used to tune the hyperparameters of the 131 model. Model performances where then evaluated in an outer loop of held out data, using again 132 a 5-Fold CV or a Leave-One-Biobank-Out-Validation (LOBOV) (Figure 1A, Methods) . We 133 assessed model performances using the mean Area Under the Curve (AUC) of the receiver-134 operator curve obtained in the outer 5-Fold CV ( Table 1 ) and considered a model's 135 performance to be sufficiently accurate at AUC > 0.7. Overall, 19 out of 20 models passed this 136 criterium, with only a single phenotypic variable, 'high-pressure', that could not be accurately 137 captured by 1 H-NMR (AUC5-Fold CV = 0.68). Strikingly, 9 out of 20 models achieved an AUC5-138 pressure lowering medication' were predicted at a more than satisfactory accuracy (AUC5-Fold 145 CV > 0.8), indicating that overall, the 1 H-NMR metabolome can be used to impute a broad 146 spectrum of common clinical variables. 147

As the performances of our models may vary per biobank due to study-specific 148 characteristics, e.g. varying study inclusion criteria or protocols for sample storage, we also 149 evaluated the variation of our model performances across biobanks. First, using a Leave-One-150

Biobank-Out-Validation (LOBOV), we evaluate how our models would perform when applied 151 to data of a new unseen biobank. As expected, mean model accuracies of the LOBOV, 152 weighted based on the size of the testing biobank, show more variation across folds ( Figure  153 S2A-B) and are generally slightly lower than the overall results of the 5-Fold CV ( Table 1) . In 154 particular, some of the smaller studies containing diseased patients showed relatively poor 155 accuracies ( Figure S2B) . Indeed, surrogate values do show cohort specific effects, but 156 interestingly, this does not necessarily affect its predictive performance within cohorts ( Figure  157 S2C). Overall, 14 out of the 20 models performed on average satisfactorily (AUCLOBOV > 0.7) 158 across all studies in the LOBOV setting. 159 Given that all models are trained on a relatively limited set of metabolic markers, we 162 investigated to what extent the produced models and predictions show mutual dependencies. 163

For this purpose, we first visualized the coefficients (betas) of the logistic Elastic-NETs 164 (Figure 2 ) to show the relative importance of the metabolites within each of the prediction 165 models. While the selection of variables for the models shows a distinct pattern, we also note 166 some similarities, as quantified by the correlations between the model coefficients ( Figure S3 ). 167

Overall, we note a clear preference for the models to include metabolites of the classes 168 "Lipoproteins" and "Lipids and related measures" over "Amino Acids". In addition, we note 169 that the models of related phenotypes also display some resemblances in the employed features, 170 for instance 'lipid medication' and 'blood_pressure_lowering_medication' share some model 171

We next evaluated correlations between the outputs of our models, from here on referred 173 to as the 'metabolic surrogates' (Figure 3 ) and compared these to correlations between the 174 original clinical variables ( Figure S1B ) in the BBMRI.nl data set. Overall, we observe that the 175 model outputs show correlation patterns and groupings that largely mimic that of the original 176 variables. For instance, model outputs trained on variables related to weight problems, i.e. 177 'obesity', 'diabetes', 'metabolic syndrome', show high mutual correlations, and moreover are 178 grouped with model outputs trained on medication usage, i.e. 'lipid medication' and 'blood 179 pressure lowering medication'. Although we observe some correlations between the outputs 180 of our different age predictors i.e. 'low age', 'middle age', 'high age', we observe that 'high 181

age' is grouped with the models for 'high hscrp', 'lipid medication' and 'blood pressure 182 lowering medication', while 'middle age' is grouped with 'current smoking' and 'alcohol use' and 'low age' with 'low white blood cell count'. This suggests that at different ages, different 184 conventional clinical variables play a role in physiology; an aspect well-known from literature 185 

The heatmap of correlations of the metabolic surrogate values of the 19 successful models, clustered based on the 198 correlation levels, between the imputed metabolic surrogate levels within BBMRI-NL.

Projection in an independent study demonstrates model accuracy 201

We performed a more extensive evaluation of the surrogate values by employing 202 Figure S9B Comparison 1) . Next, we performed the same association analyses using the 279 'obesity' surrogate as confounder. Similar to BMI, also the 'obesity' surrogate is significantly 280 higher in diabetics as compared to non-diabetics (t-test = -11.2, p = 2.48x10 !)- Figure S8B ) 281 and was associated with many of the metabolites (176 significant associations). Further 282 adjusting the MetaboWAS on T2D for 'obesity' reduced the number of significant metabolites 283 to 66 (Figure S9B Comparison 2) . 284

We then investigated to what extent adjusting for BMI or adjusting for the 'obesity' 285 surrogate yields similar metabolite markers to T2D associations, by comparing the obtained 286 estimates from both models (Figure 5) . Overall, highly similar ( ) = 0.902) associations 287 between metabolic markers and T2D are found for both models, with glucose being the most 288 significantly associated marker in both ( = 9.43 10 !)when correcting for BMI and = 289 1.6 10 !), correcting for 'obesity'). While most metabolites reported to be significantly 290 associated with T2D overlap between the two models (62 out of 227; in purple), some 291 discrepancies were observed, particularly at the significance threshold. When correcting for 292 BMI, 18 significant metabolic markers were identified, that were not identified when correcting 293 for 'obesity' (red dots, false negative rate ~ 0.11). Conversely, 7 metabolites were deemed 294 significantly associated with diabetes status when adjusting for 'obesity', but not when 295 adjusting for BMI (blue dots, false positive rate ~ 0.027). Nevertheless, overall, the differences 296 in estimated effects remain small, indicating that metabolic surrogates may prove useful to 297 account for missing data in epidemiological studies. 298 on mortality in men (HR = 1.23, p = 6.42x10 !( ), than for women (HR = 1.11, p = 3.1x10 !" ), 319 the same goes for 'blood pressure lowering medication' (men: HR = 1.3, p = 1.13x10 !* , 320 women: HR = 1.1, p = 6.39x10 !" ). In contrast, 'low hemoglobin' is associated with a higher 321 risk in women (HR = 1.5, p = 1.95x10 !#" ), than men (HR = 1.37, FDR = 2.42x10 !-). 322

To identify the minimal set of metabolic surrogates independently associating with all-323 cause mortality, we performed a stepwise (forward/backward) cox regression, adjusted for age 324 at sampling, in the LLS-SIBS dataset (Figure 7A-B Secondly, predicting continuous variables using linear ElasticNET regression models 362 emphasizes the prediction of the extremes of a phenotypic distribution, i.e. the model will fit 363 the most atypical participants, whereas the current approach emphasizes to predict the 364 commonly populated phenotypic range in which participants become at risk. Thirdly, our 365 models output a posterior probability that indicates the likelihood (a continuous score) of a 366 sample belonging to one of two labels, e.g. obese/non-obese. In effect, these posteriors 367 reconstitute part of the information lost when dichotomizing continues variables, as 368 exemplified by the observed correlation patterns between surrogates that mimic the correlation 369 patterns between the original variables. We illustrated this in our second application scenario where we showcased the use of surrogates 383 to explore potential confounding by non-assessed phenotypic variables in omics studies. While 384 use of actual phenotypic variables will always be preferred over metabolic surrogates, the 385 availability of these metabolic surrogates can thus be used to direct replication efforts or to 386 inform the design of new or follow-up studies. 387

Besides anthropometric measures and other physiological characteristics, the blood 1 H-388 NMR metabolome was previously also shown to capture aspects directly pertaining to health 389 outcomes. In particular, we and others have previously reported 1 We employed two training-evaluation procedures to get an unbiased estimate of the 503 models' possible performances (Figure 1 ). As a first scenario, we used a Double 5-Fold-Cross-504

Validation (5-Fold CV) with 5 repetitions. This procedure consists of two loops of 5FCV, one 505 internal and one external, in which we first split the dataset in testing (20%) and training (80%) 506 sets and then on the latter set we have another 5FCV repeated for 5 different times, which is 507 done for an unbiased tuning of the model (setting the correct parameter) that is finally trained 508 on the complete training dataset and tested on the left-out test data. Both 5-FoldCVs were done 509 such that the original distribution of each clinical variable is maintained as much as possible 510 (using the function createFolds from the R package caret). In the second training-testing 511 procedure, we applied a Leave-One-Biobank-Out-Validation (LOBOV), which consists of 512 holding out one of the biobanks with the considered variable available, which is then used as a 513 test set, while training on the remaining biobanks [16] . Also, in this setting, we applied a 5FCV 514 with 5 repetitions to tune the best model for each training set. 515 516

We conducted Metabolome Wide Association Studies (MetaboWAS) using the middle-518 aged cohort of the Leiden Longevity Study (LLS-PARTOFFs, 2,307 individuals, median age 519 at baseline = 59 years old). As metabolites distributions are often skewed, we first transformed 520 all metabolite measurements using a rank inverse normalization (RIN). Applying a PCA on the 521 LLS-PARTOFFs dataset revealed that the first 40 principal components explain 99% of the 522 variance in the metabolites ( Figure S9A) . Hence, the p-value of the MetaboWASes were 523

Bonferroni corrected using 40 tests, i.e. a p-value designated significant when smaller than 524 0.00125 (0.05/40) [60]. We performed 5 different MetaboWASs. 525 526 6. Associations of the metabolic surrogates to all-cause mortality 527

We used Cox proportional hazards models with follow-up time as the time scale, to test for 528 associations between the metabolic surrogate measures and incident endpoints, i.e. all-cause-529 mortality in LLS-SIBS. We checked for associations adjusting for age and sex. To avoid bias 530 due to familial correlations from pedigrees, we used robust standard errors (calculated with the 531 Huber sandwich estimator) implemented in R coxph function. Considering that the population 532 in LLS-SIBS has a different inclusion criterium for men (age > 89 years old) and women (age 533 > 91 years old), we also evaluated associations separately in men and women. P-values were 534 corrected using Benjamini Hochberg separately for each selection (all individuals, men and 535 women) and considered significant the FDR < 0.05. To select potentially interesting metabolic 536 surrogate, we used a stepwise procedure for the Cox regression models, corrected for sex and 537 

What are Biomarkers?

Biomarkers: Potential uses and limitations

Biomarkers: current perspectives and future prospects

Missing value imputation in high-dimensional phenomic data: 567 imputable or not, and how?

A multiple-phenotype imputation method for genetic studies

Characterization of missing values in untargeted MS-based metabolomics 572 data and evaluation of missing data handling strategies

Multiple imputation by chained 575 equations: what is it and how does it work?

K-Nearest Neighbor in Missing Data 578 Imputation

Potential Impact and Study Considerations of Metabolomics in 580

Cardiovascular Health and Disease A Scientific Statement From the American Heart 581 Association

Integration of epidemiologic, pharmacologic, genetic and gut microbiome 584 data in a drug-metabolite atlas

Glycemic Control in Type 2 Diabetes

Large-scale plasma metabolome analysis reveals alterations 590 in HDL metabolism in migraine

Microbial Impact on Plasma Metabolites is Linked to the 593

Cardiovascular Risk and Phenotypes

Metabolic profiling of intra-and extracranial carotid artery 596 atherosclerosis

Association of branched-chain amino acids and other circulating 599 metabolites with risk of incident dementia and Alzheimer's disease: A prospective study 600 in eight cohorts

Metabolomics Repository as Biomarker of Age-related Disease

A metabolic profile of all-cause mortality risk identified in an 606 observational study of 44,168 individuals

Metabolomic Profiles of Body Mass Index in the Framingham Heart Study 609

Reveal Distinct Cardiometabolic Phenotypes

Metabolite patterns predicting sex and age in participants of the 612

Karlsruhe Metabolomics and Nutrition (KarMeN) study'

Evidence of genetic enrichment for exceptional survival using a 615 family approach: the Leiden Longevity Study

Metabolic Signatures of Adiposity in Young Adults: Mendelian 618

Randomization Analysis and Effects of Weight Change'

Quantitative serum 621 nuclear magnetic resonance metabolomics in cardiovascular epidemiology and genetics

Plasma protein patterns as comprehensive indicators of health

BIOMARKERS RELATED 627 TO AGING IN HUMAN POPULATIONS

Application to Clinical and Public Health Practice: clinical use 631 of inflammatory markers in patients with cardiovascular diseases: a background paper

Body mass index, waist circumference, and risk of coronary heart 635 disease: a prospective study among men and women

Blood Groups and Red Cell Antigens. National Center for 638 Biotechnology Information (US)

Ageing and the Glomerular Filtration Rate: Truths and 640 Consequences

Blood pressure and ageing

Lipids, lipoproteins, lifestyle, adiposity and fat-free mass during 644 middle age: the Fels Longitudinal Study

Molecular mechanisms of insulin resistance in type 2 diabetes mellitus', World 647

Metabolic Syndrome and Insulin 649 Resistance: Underlying Causes and Modification by Exercise Training

The effect of age on insulin resistance 655 and secretion: a review

Leptin Resistance and 657 Obesity

Leptin and high-sensitivity C-reactive protein and their 660 interaction in the metabolic syndrome in middle-aged subjects

Leptin Predicts a Worsening of the Features of the Metabolic 663

Syndrome Independently of Obesity

Leptin and incident type 2 diabetes: risk or protection?

New insight into adiponectin role in obesity and obesity-related diseases

Decreased plasma adiponectin 671 concentrations in women with low-grade C-reactive protein elevation

Associations of elevated Interleukin-6 and C-Reactive protein levels 674 with mortality in the elderly * * Access the

Active smoking and a history of 678 smoking are associated with enhanced prostaglandin F2α, interleukin-6 and F2-679 isoprostane formation in elderly men

Elevated 682 white cell count in acute coronary syndromes: relationship to variants in inflammatory 683 and thrombotic genes

Sex differences in the association between diabetes and risk of 686 cardiovascular disease, cancer, and all-cause and cause-specific mortality: a systematic 687 review and meta-analysis of 5,162,654 participants

Impact 690 of gender on statin efficacy

Sex-specific Associations Between 693

Serum Hemoglobin Levels and the Risk of Cause-specific Death in Korea Using the 694 National Health Insurance Service-National Health Screening Cohort (NHIS HEALS)

Mortality in women and men in relation to smoking

Gender and the Burden of Disease 700

Attributable to Obesity

Sex differences in lipid and 703 lipoprotein metabolism

Hs-CRP and all-cause, cardiovascular, and cancer mortality risk: A meta-706 analysis

Gender differences 709 in old age mortality: roles of health behavior and baseline health status

713 'Health behaviors and survival among middle-aged and older men and women in the 714 NHANES I Epidemiologic Follow-up Study

Gender difference in cardiovascular risk factors in the elderly with 717 cardiovascular disease in the last stage of lifespan: The PROTEGER study

Power and Predictive Accuracy of Polygenic Risk Scores

Prospects for using risk scores in polygenic medicine

Genome-wide polygenic scores for common diseases identify 724 individuals with risk equivalent to monogenic mutations

The Polygenic Score Catalog as an open database for reproducibility 727 and systematic evaluation

An atlas of polygenic 730 risk score associations to highlight putative causal relationships across the human 731 phenome

Metabolite profiling and cardiovascular event risk: a prospective study 733 of 3 population-based cohorts

Circulating metabolites and the risk of type 2 diabetes: a 736 prospective study of 11,896 young adults from four Finnish cohorts

Metabolic biomarker profiling for identification of susceptibility to severe 740 pneumonia and COVID-19 in the general population', eLife

Adjusting batch effects in microarray expression 743 data using empirical Bayes methods

HMDB 4.0: the human metabolome database for

Quantitative Serum Nuclear Magnetic Resonance Metabolomics in Large-Scale 750 Epidemiology: A Primer on -Omic Technologies

Estimation of the Concentration of 753 Low-Density Lipoprotein Cholesterol in Plasma, Without Use of the Preparative 754 Ultracentrifuge

Andersson Franko Mikael, Obergfell Achim, Gabrielsen Anders

Level and the Risk of Death or Recurrent Cardiovascular Events 758 in Patients With Myocardial Infarction: a Healthcare-Based Study

between "normal" and "at risk" levels for each risk factor (in Table1 and in which (∈ (0, ∞)) represents the "shrinkage parameter" and (∈ (0,1)) is the mixing 497 parameter balancing the L1 and L2 norm regularizations. We fixed the mixing parameter at